SABS
NASDAQ · Biotechnology
Sab Biotherapeutics Inc
$3.22
-0.08 (-2.28%)
Open$3.34
Previous Close$3.29
Day High$3.34
Day Low$3.14
52W High$5.15
52W Low$1.85
Volume—
Avg Volume610.3K
Market Cap304.80M
P/E Ratio22.96
EPS$-1.42
SectorBiotechnology
Analyst Ratings
Strong Buy
17 analysts
Price Target
+877.0% upside
Current
$3.22
$3.22
Target
$31.41
$31.41
$26.29
$31.41 avg
$48.84
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 92.27M | 83.15M | 89.97M |
| Net Income | 5.58M | 4.38M | 5.69M |
| Profit Margin | 6.1% | 5.3% | 6.3% |
| EBITDA | 11.07M | 10.58M | 10.22M |
| Free Cash Flow | 5.66M | 4.59M | 4.29M |
| Rev Growth | -8.1% | +18.1% | +3.5% |
| Debt/Equity | 0.85 | 0.76 | 0.75 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |